Leveraging its expertise in both detection reagents and antibodies, AnaSpec has introduced a new series of labeled Anti-CD-3ε and anti-CD79α antibodies. - August 29, 2007 - AnaSpec, Eurogentec Group

Today AnaSpec, one of the world’s largest providers of custom and catalog peptides, introduced thirty-six (36) new peptides for drug discovery research. Protease-Activated Receptor-4; PAR-4 Agonist; amide; human Amyloid Precursor Protein (APP) (667-676); Swedish mutation Colivelin AGA-(C8R) HNG17;... - August 28, 2007 - AnaSpec, Eurogentec Group

This week AnaSpec introduced the SensoLyteTM 520 TACE Assay Kit, offering fluorescence detection at the industry’s longest wavelengths. With higher fluorescence quantum yield and longer emission wavelength, this kit shows less autofluorescence interference from test compounds and cellular components,... - August 28, 2007 - AnaSpec, Eurogentec Group

As compiled by Stanford University’s Highwire Press, the number of published papers that cite AnaSpec’s products has passed 500. - August 26, 2007 - AnaSpec, Eurogentec Group

Continuing in its commitment to rapidly expand its antibody offerings, AnaSpec, a leading provider of integrated proteomics solutions, added ten (10) new antibodies to its growing collection of catalog antibodies. Anti-MAP1-LC3 beta (NT) - Cat# 29783, 50 µg Host:rabbit polyclonal; Species Rectivity:Human;... - August 25, 2007 - AnaSpec, Eurogentec Group

One of the world’s largest providers of catalog peptides, AnaSpec introduced its CEF Control Peptide Pool. Previously available only individually, this group of peptides is now available pooled. The CEF Control Peptide Pool is a group of 32 peptides, 8-12 amino acids in length, with sequences... - August 23, 2007 - AnaSpec, Eurogentec Group

Continuing in its commitment to rapidly expand its antibody offerings, AnaSpec, a leading provider of integrated proteomics solutions, added twenty-eight (28) new antibodies to its growing collection of catalog antibodies. - August 22, 2007 - AnaSpec, Eurogentec Group

Samaritan announced that it has entered into an exclusive licensing agreement with Georgetown University for a patent covering the Peripheral Benzodiazepine Receptor (PBR) which has led to Cancer drug candidates with the ability to inhibit cancerous tumors; and an imaging technique that could possibly distinguish cancerous tumors for a more targeted and improved chemotherapy. - August 21, 2007 - Samaritan Pharmaceuticals

One of the world’s largest providers of unusual amino acids, today AnaSpec announced the release of its 2007-2009 Combinatorial Chemistry catalog. - August 18, 2007 - AnaSpec, Eurogentec Group

Samaritan Pharmaceuticals has exclusively licensed a patent application entitled "Structure Based Drug Design of Steroid Inhibitors" from Georgetown University. - August 16, 2007 - Samaritan Pharmaceuticals

Reporting on results gathered from its antibody and assay kit departments, AnaSpec has released data that supports the efficacy of its MOG(35-55) peptide. Analytical results reported the following: AnaSpec’s mouse/rat MOG(35-55) peptide induced EAE in C57BL/6 mice with 100% incident (10/10).... - July 28, 2007 - AnaSpec, Eurogentec Group

AnaSpec has introduced acetylated, mono-methylated, di-methylated and tri-methylated Lysine for the synthesis of histone peptides. The use of these building blocks, although not limited to making synthetic histone peptides, provides additional tools for researchers to help unravel the “histone... - July 28, 2007 - AnaSpec, Eurogentec Group

Today AnaSpec, one of the world’s largest providers of custom and catalog peptides, introduced fourteen (14) new peptides for drug discovery research. HIV Nef (68–76) - Cat# 61673 This HIV nef peptide 68 to 76 amino acids was identified in HIV-infected individuals. It is a B7 restricted... - July 27, 2007 - AnaSpec, Eurogentec Group

Continuing in its commitment to rapidly expand its antibody offerings, AnaSpec, a leading provider of integrated proteomics solutions, added twelve (12) new antibodies to its growing collection of catalog antibodies. The targeted research area for these antibodies is signal transduction and matrix metalloproteinases. Anti-DEFCAP... - July 26, 2007 - AnaSpec, Eurogentec Group

Today AnaSpec, one of the world’s largest providers of custom and catalog peptides, introduced ten (10) new peptides for drug discovery research. MUC4 - Cat# 61339 This peptide is derived from the tandem repeat of Muc 4 mucin protein. Mucins are highly O-glycosylated proteins which polymerize... - July 25, 2007 - AnaSpec, Eurogentec Group

The Tampa-based contract research organization acquires a brand new building. - July 23, 2007 - Xcelience, LLC

This week AnaSpec, one of the world’s largest providers of custom and catalog peptides, introduced eleven (11) new peptides for drug discovery research. - July 22, 2007 - AnaSpec, Eurogentec Group

Cathelicidins are cationic peptides that have broad-range antimicrobial activity. These peptides belong to the family of anti-microbial peptides which form part of the host’s important innate immunity mechanism. - July 20, 2007 - AnaSpec, Eurogentec Group

AnaSpec has introduced its newest antibody solutions – anti-MMP-1 (Hinge) and anti-MMP-13 (Hinge) antibodies. Strategically raised against the hinge regions of MMP-1 and MMP-13, the epitopes do not overlap the catalytic domain and will not influence the activity of the MMP ferment in experiments.... - July 19, 2007 - AnaSpec, Eurogentec Group

At the 2007 annual conference of the American Peptide Society, AnaSpec presented a technical poster that described the facile synthesis of a hydrocarbon-stapled peptide. Asymmetric synthesis of (S)-Fmoc-α-(2’-pentenyl)-alanine was successfully accomplished via an Ala-Ni (II)-BPB-complex [3]... - July 14, 2007 - AnaSpec, Eurogentec Group

At the 2007 annual conference of the American Peptide Society, AnaSpec presented a “late-breaking” technical poster that described in vivo imaging using a tissue-specific near infrared fluorescent peptide conjugate. Extracellular matrix proteins that contain the Arg-Gly-Asp (RGD) sequence,... - July 13, 2007 - AnaSpec, Eurogentec Group

The June issue of PharmaChem, an Italian journal covering the drug discovery industry, featured an article written by AnaSpec called “Peptides as Antigens.” The technical article, written by Dr. Daniel Li and Cecilia Po, outlines the advantages and methodologies behind using peptides as antigens. Company... - June 24, 2007 - AnaSpec, Eurogentec Group

Leveraging one of the world’s largest collections of amyloid peptides, AnaSpec has introduced its latest development in novel solutions for amyloid-related research - the new SensoLyte™ 520 Beta-Secretase Assay Kit. Beta-secretase catalyzes a key step in the production of beta-amyloid peptides... - June 22, 2007 - AnaSpec, Eurogentec Group

Bio-Synthesis joined with Protein Lounge to bring all the vital and necessary databases to one place. Users have access to the Protein Database, Peptide Antigen Database, and the siRNA database. - June 21, 2007 - Bio-Synthesis Inc.

Drawing on its broad portfolio of MOG (35-55) and other multiple sclerosis (MS) experimental autoimmune encephalomyelitis (EAE)-related peptides, AnaSpec has just released its new line of SensoLyte™ Anti - MOG ELISA Kits - the industry’s first and only anti-MOG ELISA kits. Myelin oligodendrocyte... - June 16, 2007 - AnaSpec, Eurogentec Group

At the 2007 Experimental Biology conference in Washington, DC, AnaSpec prepared a technical poster entitled, "A Sensitive Fluorimetric Assay for Detection of beta-Secretase Activity Using a Novel FRET Peptide Substrate." The poster documented the following findings: • A highly sensitive... - June 08, 2007 - AnaSpec, Eurogentec Group

Peptides are complex molecules and each peptide sequence is unique with regard to its chemical and physical properties. Peptides are synthesized by the solid-phase method using Fmoc chemistry on an Omega 396 multiple peptide synthesizer from Advanced ChemTech. - June 01, 2007 - Bio-Synthesis Inc.

Bioactivation of drug candidates resulting in chemically reactive, electrophilic metabolites have always presented a major challenge to pharmaceutical companies. Moreover, the measurement of these metabolites has been hampered by the lack of an effective quantitative method. QA-GSH is a novel new tool... - May 31, 2007 - AnaSpec, Eurogentec Group

The Tampa-based Contract Research Organization signed a partnership that will form new opportunities in the pharmaceutical industry. - May 24, 2007 - Xcelience, LLC

The insulin receptor is a transmembrane receptor that belongs to the tyrosine kinase receptors class. It is a heterotetrameric glycoprotein composed of disulfide-linked subunits in a β-α-α-β configuration. This transmembrane receptor consists of 95kDa β-subunit, a single transmembrane... - May 23, 2007 - AnaSpec, Eurogentec Group

While West Nile virus (WNV) has had significant outbreaks throughout the world since it was first identified, commercially available assay kits for the detection of WNV protease inhibitors had not been developed until now. With the SensoLyte™ series of WNV Protease Assay Kits AnaSpec, a worldwide... - May 17, 2007 - AnaSpec, Eurogentec Group

Interleukin-32 (IL-32), whose expression is increased following activation by IL-2, was initially identified as a transcript (NK4) selectively expressed in lymphocytes and NK cells.1 - April 18, 2007 - AnaSpec, Eurogentec Group

At the 2007 annual conference of the Association of Biomolecular Resource Facilities, AnaSpec presented a technical poster that compared the synthesis of a fluorescent peptide using two types of resins. The results of the poster indicated that the use of an unprotected resin was just as effective as... - April 13, 2007 - AnaSpec, Eurogentec Group

Utilizing its proprietary HiLyte Fluor™ technology, AnaSpec has introduced dye solutions for far red to NIR imaging. AnaSpec’s HiLyte Fluor™ 647, HiLyte Fluor™ 680, and HiLyte Fluor™ 750 provide AnaSpec with a range of dyes that cover the spectrum. AnaSpec has also introduced... - April 11, 2007 - AnaSpec, Eurogentec Group

The labeling of proteins and antibodies with fluorescent dyes can play a crucial role in flow cytometry, immunohistochemistry and fluorescent in-situ hybridization techniques. Incorporating its high performance HiLyte Fluor™ dyes in a ready-to-use kit, AnaSpec has introduce its new line of AnaTag™... - April 04, 2007 - AnaSpec, Eurogentec Group

In an effort to optimize the online experience of its customers, AnaSpec, a worldwide provider of integrated proteomics solutions, has moved its website to a faster, dedicated server. AnaSpec sales & marketing manager, Violeta Rajkovska, MBA, stated, “With the huge number of catalog products... - March 28, 2007 - AnaSpec, Eurogentec Group

Advaxis’ John Rothman Recognized as one of 20 Notable People in R&D - March 16, 2007 - Advaxis

AnaSpec, a worldwide provider of integrated proteomics solutions, announced today that the name of their flagship line of high-performance assay kits has been changed from EnzoLyte to SensoLyte™. AnaSpec sales & marketing manager, Violeta Rajkovska, MBA, noted, “The new name demonstrates... - March 14, 2007 - AnaSpec, Eurogentec Group

Xcelience's implementation of the CFS1200 will allow its formulation scientists the opportunity to accelerate the drug development timeframe. - March 13, 2007 - Xcelience, LLC

Xcelience achives its third successful audit. - March 09, 2007 - Xcelience, LLC

XpertXchange will initiate dialogue between Xcelience scientists and drug development professionals. - March 02, 2007 - Xcelience, LLC

Instead of using the usual cancer-fighting modalities, surgery, chemotherapy, or radiation, researchers from a drug development company called Advaxis, have embarked on a novel approach to fighting cancer: Engaging the immune system to attack cancer in the same the way it would a flu vaccine, by creating... - February 27, 2007 - Advaxis

The launch of Xpert Consulting will provide supplemental services to assist clients. - January 17, 2007 - Xcelience, LLC

At the annual conference of the American Society for Cell Biology, AnaSpec presented a technical poster documenting improved technology for MMP detection assays. In a previous poster, AnaSpec documented the use of highly sensitive FRET-peptide substrates for MMP detection. The latest poster documented... - December 19, 2006 - AnaSpec, Eurogentec Group

The substitution of the fluorine in place of hydrogen in building blocks, such as amino acids, has produced molecules with enhanced physiological activities (1-2). Some of these are antibacterial, antihypertensive and antitumoral (3). One reason for the enhanced activity is that fluorine forms a strong... - December 12, 2006 - AnaSpec, Eurogentec Group

Swiss Medica, Inc. (OTCBB: SWME) announced today its intention to pursue military and international contracts with the appointment of Mr. Chad Christensen, Managing Director of Christensen Co., as Strategic Business Advisor. With a distinguished career in international banking, and advisor to several... - July 30, 2006 - SwissMedica Support Group

AnaSpec, a leading provider of integrated proteomics solutions, has introduced an extensive new line of reagents and kits for the study of protein phosphorylation. Cellular phosphorylation is a reversible, covalent modification of a protein or lipid that serves to modify the activity of the phosphorylated... - June 06, 2006 - AnaSpec, Eurogentec Group

BioTX has finished the development of an application based, light guided manual pipetting system called WellAware which is ideal for forensic, paternity, life science, pharmaceutical, preclinical and chemistry labs. WellAware provides lab managers with an inexpensive alternative or supplement to full automation. WellAware is configured right out of the box for PCR, DNA sequencing, genotyping, microplate transpositions, dilutions, normalizations, microplate reformatting and cherry-picking. - May 25, 2006 - BioTX Automation, Inc.

Cactus Botanics Limited, in cooperation with its Chinese manufacturing operations, has completed expansion of its production capabilities for Policosanol (Octacosanol 65%). - November 12, 2005 - Cactus Botanics Limited

Cactus Botanics, a leading raw material supplier, announces the completion of development and introduction to the market of Sesamin 90% HPLC, currently the only Chinese supply of this level. - November 07, 2005 - Cactus Botanics Limited